Genetic and multi-omic studies have identified genes such as insulin-like growth factor 2 (IGF2), Wnt/b-catenin, TP53, and others as potential drivers of ACC leading to the development of targeted therapies for ACC. This evidence concerns the gene IGF2 and adrenal cortex carcinoma.